Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eftilagimod alpha
- Development stage
- Phase 3
- Lead developer
- Immutep
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Eftilagimod alpha is a recombinant fusion protein and immunotherapy drug developed for cancer treatment. It is a soluble version of the immune checkpoint molecule LAG-3, consisting of the four extracellular domains of LAG-3 fused to the Fc region of human IgG1. As an MHC class II agonist and antigen-presenting cell (APC) activator, it binds with high affinity to MHC class II molecules on dendritic cells and monocytes. This interaction leads to APC maturation and migration to lymph nodes as well as enhanced cross-presentation of antigens to T cells—particularly cytotoxic CD8+ T cells—resulting in increased anti-tumor immune responses. Eftilagimod alpha is being investigated primarily for metastatic breast cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, squamous cell cancer, and COVID-19 infections. It is administered by subcutaneous injection.
- Brand names
- ImmuFact
- Other names
- eftilagimod alfa
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on eftilagimod alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eftilagimod alpha.